JPMorgan cuts target to USD 145.00 for Rhythm Pharmaceuticals stock
Published on 10/17/2026 at 19:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst targets and market dates
- JPMorgan lowered its target to USD 145.00 on October 15, 2026.
- RBC set a USD 159.00 target on October 8, 2026.
- Rhythm Pharmaceuticals stock was last at USD 86.17 on October 16, 2026, down 2.05 percent versus the Nasdaq prior close.
- Rhythm Pharmaceuticals is scheduled to report on November 3, 2026.
JPMorgan Chase & Co. lowered its price target for Rhythm Pharmaceuticals from USD 146.00 to USD 145.00 on October 15, 2026, while keeping an Overweight rating, according to MarketBeat. At USD 86.17, that target stands 68.27 percent above the Nasdaq price last quoted on October 16, 2026. Rhythm Pharmaceuticals was last at USD 86.17 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.05 percent versus the prior close of October 15, 2026.
Revenue provides the operating anchor
Rhythm's second-quarter 2026 revenue reached USD 71.3 million, up 47.00 percent from the year-earlier quarter, while the company remained loss-making. Simply Wall St reported that the quarter's loss was USD 50.4 million and earnings per share were a USD 0.73 loss. The figures frame the analyst targets against commercial growth that has not yet translated into positive earnings.
Range shows room below the high
The USD 74.50 to USD 122.20 52-week range places the latest price 15.66 percent above the low and 29.49 percent below the high, based on the October 16, 2026 quote. Trading volume was 364,054 shares against an average of 666,567, leaving the session at 54.61 percent of its average volume. These levels describe the stock's position without assigning a forecast.
Valuation and November 3 results
Rhythm's market capitalization was USD 5.9 billion on October 16, 2026. The next reported corporate date is November 3, 2026, before the market opens, according to Gekko. A separate analyst update from Markets Insider said RBC Capital raised its target from USD 155.00 to USD 159.00 on October 8, 2026.
Comparison with peers
RYTM (Nasdaq, USD): minus 2.05 percent, market capitalization USD 5.9 billion
Viking Therapeutics (Nasdaq, USD): minus 8.04 percent, market capitalization USD 3.2 billion
Structure Therapeutics (Nasdaq, USD): minus 5.00 percent, market capitalization USD 1.2 billion
Market value remains the anchor
Rhythm Pharmaceuticals combines a 47.00 percent year-over-year revenue increase in the second quarter of 2026 with a USD 50.4 million quarterly net loss. The October 16 price therefore sits between a 52-week low of USD 74.50 and a high of USD 122.20, while analyst targets remain well above the latest Nasdaq level.
Market context: Market report S&P 500.
Rhythm Pharmaceuticals market facts
- Company: Rhythm Pharmaceuticals, Inc.
- ISIN: US76243J1051
- Ticker: RYTM
- Primary exchange: Nasdaq
- Price Nasdaq (as of October 16, 2026, 4:00 p.m. ET): USD 86.17
- Change versus prior close: minus 2.05 percent
- Market capitalization: USD 5.9 billion (as of October 16, 2026)
- 52-week range: USD 74.50-122.20 (as of October 16, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
